Clinical Trial Details

MK-3475-158/KEYNOTE-158

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Advanced Cancer
Study Type: Interventional
Phase: Phase II
Study Start Date: 12/09/2015
Study Completion Date: TBD

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

NCT Number

NCT02628067

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Merck Sharp & Dohme Corp

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female